275 related articles for article (PubMed ID: 19223502)
1. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Shiozawa K; Nakanishi T; Tan M; Fang HB; Wang WC; Edelman MJ; Carlton D; Gojo I; Sausville EA; Ross DD
Clin Cancer Res; 2009 Mar; 15(5):1698-707. PubMed ID: 19223502
[TBL] [Abstract][Full Text] [Related]
2. In vitro test-system for chemo- and thermosensitivity: an analysis of survival fractions and cell-cycle distributions in human Ewing's sarcomas as a modelfor tumors in pediatric oncology.
Debes A; Rommel F; Breise M; Willers R; Göbel U; Wessalowski R
Klin Padiatr; 2002; 214(4):223-9. PubMed ID: 12165906
[TBL] [Abstract][Full Text] [Related]
3. Timed sequential therapy of acute leukemia with flavopiridol: in vitro model for a phase I clinical trial.
Karp JE; Ross DD; Yang W; Tidwell ML; Wei Y; Greer J; Mann DL; Nakanishi T; Wright JJ; Colevas AD
Clin Cancer Res; 2003 Jan; 9(1):307-15. PubMed ID: 12538483
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy for acute myeloid leukemias with cytosine arabinoside, daunorubicin, etoposide, and mitoxantrone may cause permanent oligoasthenozoospermia or amenorrhea in middle-aged patients.
Lemez P; Urbánek V
Neoplasma; 2005; 52(5):398-401. PubMed ID: 16151584
[TBL] [Abstract][Full Text] [Related]
5. Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemia.
Gojo I; Tan M; Fang HB; Sadowska M; Lapidus R; Baer MR; Carrier F; Beumer JH; Anyang BN; Srivastava RK; Espinoza-Delgado I; Ross DD
Clin Cancer Res; 2013 Apr; 19(7):1838-51. PubMed ID: 23403629
[TBL] [Abstract][Full Text] [Related]
6. [Induction of Ph-negative normal clone and long-term survival by combined treatment with G-CSF plus middle dose cytosine arabinoside for patients with chronic myeloid leukemia in blastic transformation].
Katagiri T; Miyazawa K; Uchida Y; Hayashi S; Iwama H; Shyohji N; Kawakubo K; Shimamoto T; Inatomi Y; Kuriyama Y; Yaguchi M; Nehashi Y; Ohyashiki K; Toyama K
Rinsho Ketsueki; 1998 Dec; 39(12):1149-56. PubMed ID: 10028846
[TBL] [Abstract][Full Text] [Related]
7. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias.
Karp JE; Passaniti A; Gojo I; Kaufmann S; Bible K; Garimella TS; Greer J; Briel J; Smith BD; Gore SD; Tidwell ML; Ross DD; Wright JJ; Colevas AD; Bauer KS
Clin Cancer Res; 2005 Dec; 11(23):8403-12. PubMed ID: 16322302
[TBL] [Abstract][Full Text] [Related]
8. Complementary antineoplastic activity of the cytosine nucleoside analogues troxacitabine (Troxatyl) and cytarabine in human leukemia cells.
Bouffard DY; Jolivet J; Leblond L; Hamelin B; Ouellet F; Barbeau S; Richard A; Gourdeau H
Cancer Chemother Pharmacol; 2003 Dec; 52(6):497-506. PubMed ID: 12955470
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo histone deacetylase inhibitor therapy with vorinostat and paclitaxel in ovarian cancer models: does timing matter?
Modesitt SC; Parsons SJ
Gynecol Oncol; 2010 Nov; 119(2):351-7. PubMed ID: 20673975
[TBL] [Abstract][Full Text] [Related]
10. Induction of S phase cell arrest and caspase activation by polysaccharide peptide isolated from Coriolus versicolor enhanced the cell cycle dependent activity and apoptotic cell death of doxorubicin and etoposide, but not cytarabine in HL-60 cells.
Hui KP; Sit WH; Wan JM
Oncol Rep; 2005 Jul; 14(1):145-55. PubMed ID: 15944782
[TBL] [Abstract][Full Text] [Related]
11. Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.
Xue K; Gu JJ; Zhang Q; Mavis C; Hernandez-Ilizaliturri FJ; Czuczman MS; Guo Y
J Cancer Res Clin Oncol; 2016 Feb; 142(2):379-87. PubMed ID: 26314218
[TBL] [Abstract][Full Text] [Related]
12. Effect of interleukin 3 on cytosine arabinoside-mediated cytotoxicity of leukemic myeloblasts.
Brach M; Klein H; Platzer E; Mertelsmann R; Herrmann F
Exp Hematol; 1990 Aug; 18(7):748-53. PubMed ID: 1696204
[TBL] [Abstract][Full Text] [Related]
13. Molecular sequelae of histone deacetylase inhibition in human retinoblastoma cell lines: clinical implications.
Poulaki V; Mitsiades CS; Kotoula V; Negri J; McMullan C; Miller JW; Marks PA; Mitsiades N
Invest Ophthalmol Vis Sci; 2009 Sep; 50(9):4072-9. PubMed ID: 19387079
[TBL] [Abstract][Full Text] [Related]
14. Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.
Fang HB; Ross DD; Sausville E; Tan M
Stat Med; 2008 Jul; 27(16):3071-83. PubMed ID: 18186545
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration.
Bible KC; Kaufmann SH
Cancer Res; 1997 Aug; 57(16):3375-80. PubMed ID: 9269999
[TBL] [Abstract][Full Text] [Related]
16. Augmentation of 1-beta-D-arabinofuranosylcytosine cytotoxicity in human tumor cells by inhibiting drug efflux.
Chan TC
Cancer Res; 1989 May; 49(10):2656-60. PubMed ID: 2713849
[TBL] [Abstract][Full Text] [Related]
17. A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Yang GS; McCulloch EA
Hematol Pathol; 1992; 6(3):125-30. PubMed ID: 1385380
[TBL] [Abstract][Full Text] [Related]
18. Intracellular cytosine arabinoside accumulation and cytosine arabinoside triphosphate formation in leukemic blast cells is inhibited by etoposide and teniposide.
Ehninger G; Proksch B; Wanner T; Schuler U; Busch FW; Schmidt H; Schleyer E; Jaschonek K; Hiddemann W
Leukemia; 1992 Jun; 6(6):582-7. PubMed ID: 1602795
[TBL] [Abstract][Full Text] [Related]
19. Development of a cell kinetic approach to curative therapy of acute myelocytic leukemia in remission using the cell cycle-specific drug 1-beta-D-arabinofuranosylcytosine in a rat model.
Vaughan WP; Burke PJ
Cancer Res; 1983 May; 43(5):2005-9. PubMed ID: 6572561
[TBL] [Abstract][Full Text] [Related]
20. Interaction of cyclosporin A and etoposide. Clinical and in vitro assessment in blast phase of chronic myeloid leukaemia.
Maia RC; Noronha H; Vasconcelos FC; Rumjanek VM
Clin Lab Haematol; 1997 Sep; 19(3):215-7. PubMed ID: 9352149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
